Scientists just hijacked one of nature’s deadliest pathogens to watch magic mushrooms rewire the brain. They stripped a rabies virus of its ability to kill, then used it as a microscopic tracer to map exactly how psilocybin rebuilds neural circuits. The study, published today in Cell, shows the drug doesn’t just grow new brain connections. It redirects traffic, weakening the loops that trap people in depression.
About 16 million American adults live with major depression each year. A third of them don’t respond to standard antidepressants. But clinical trials show that one dose of psilocybin can lift symptoms for weeks or months. That’s extraordinary. Most antidepressants take weeks just to start working, and many people need them indefinitely.
The durability puzzled researchers. They knew psilocybin sprouted new dendritic spines on neurons: tiny thorn-like branches that serve as docking stations for chemical signals. But which parts of the brain were plugging into these new ports? Previous mapping techniques could only show general connectivity patterns, not trace individual circuit changes across the whole brain.
Alex Kwan’s team at Cornell University needed a tool that could jump from neuron to neuron and light up entire pathways. They found it in a modified rabies virus. The deadly pathogen spreads by jumping across synapses between neurons. Strip away its ability to replicate, and you have a precision tracer. It infects one starter cell, then hops backward exactly one synapse and stops. Every neuron feeding signals to that cell lights up. The technique, called monosynaptic tracing, revealed a brain-wide rewiring map.
Breaking the Rumination Circuit
The maps showed psilocybin acting like a neural traffic engineer. It strengthened connections from sensory and perceptual areas down to subcortical regions: the pathways that translate what you see and feel into physical action and emotional response. At the same time, it weakened feedback loops within the cortex itself.
Those weakened loops matter. In major depression, the brain’s default mode network runs too hot. This network, which includes the retrosplenial cortex in mice, keeps your mind turned inward. It’s the voice that replays failures, predicts catastrophes, and locks you in self-focused rumination. Psilocybin appears to turn down the volume on these circuits while amplifying the brain’s connection to external reality.
The researchers found the drug affected different neuron types in opposite ways. Pyramidal tract neurons, which project signals out to the body and deeper brain structures, got stronger. Intratelencephalic neurons, which loop back to other cortex areas, got weaker. The drug was selective, not scattershot.
“With psilocybin, it’s like we’re adding all these roads to the brain, but we don’t know where the roads go,” said Alex Kwan, professor of biomedical engineering at Cornell and the paper’s senior author. “Here we use the rabies virus to read out the connectivity in the brain, because these viruses are engineered in nature to transmit between neurons. That’s how they’re so deadly. It jumps a synapse and goes from one neuron to another.”
Your Trip Draws the Map
The most clinically relevant finding: the rewiring depends on what your brain does during the experience. When researchers chemically silenced the retrosplenial cortex during psilocybin treatment, the expected connectivity changes from that region never materialized. Neural activity during the trip determines which new roads get paved.
This gives biological weight to “set and setting,” the idea that your environment and mental state during a psychedelic experience shape its therapeutic value. The drug supplies neuroplasticity, the raw capacity for change. But your brain activity during those crucial hours determines which circuits strengthen and which fade.
That insight opens new treatment strategies. Researchers might pair psilocybin with specific cognitive behavioral therapy exercises that activate healthy thought patterns during the peak experience. Or combine it with transcranial magnetic stimulation to boost activity in underactive regions while the drug makes the brain maximally plastic. You could theoretically steer the rewiring away from pathological circuits and toward adaptive ones.
“That opens up many possibilities for therapeutics, how you maybe avoid some of the plasticity that’s negative and then enhance specifically those that are positive,” Kwan noted.
The work moves psychedelic psychiatry from observing general mood improvements to understanding precise circuit-level changes. Clinical trials can now ask not just “does it work?” but “which circuits changed, and did those changes predict who got better?” The drug induces a temporary altered state, but the physical rewiring persists. The brain remembers the trip long after the experience fades.
For the 5 million Americans with treatment-resistant depression, that persistence matters. It’s the difference between a temporary reprieve and a lasting remission, between managing symptoms and potentially resolving them. The rabies virus maps show us where the roads lead.
Cell: 10.1016/j.cell.2025.11.009
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.